Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
Journal
JHEP reports : innovation in hepatology
Journal Volume
5
Journal Issue
10
Date Issued
2023-10
Author(s)
Lim, Young-Suk
Chan, Henry L Y
Ahn, Sang Hoon
Seto, Wai Kay
Ning, Qin
Agarwal, Kosh
Janssen, Harry L A
Pan, Calvin Q
Chuang, Wan Long
Izumi, Namiki
Fung, Scott
Shalimar, null
Brunetto, Maurizia
Hui, Aric Josun
Chang, Ting-Tsung
Lim, Seng Gee
Abramov, Frida
Flaherty, John F
Wang, Hongyuan
Yee, Leland J
Gane, Edward
Hou, Jinlin
Buti, Maria
Abstract
Antiviral therapy may attenuate the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to explore how tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) affect HCC risk in patients with CHB.
Subjects
REACH-B; aMAP; antiviral therapy; incidence; mPAGE-B
SDGs
Type
journal article